Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...

Needham & Company LLC reaffirmed their hold rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a ...

Vertex Pharmaceuticals (NASDAQ ... Judging by the results, the company may not have a winner on its hands. The candidate is already being considered for approval by regulators at the Food and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that causes back and ...